Galaxy Biotech, LLC

Novartis Ag

Glaxosmithkline LLC

Lihong Wang

Maximiliano Vasquez

Kyung Jin Kim

Hangil Park

Ngocdiep T Le

Douglas J DeMarini

Francisco Henriquez

Yi Ding

April Zhang

Douglas J Demarini

Douglas J Demarin

Douglas J De Marini

The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Highly potent antibodies binding to death receptor 5

Highly potent antibodies binding to death receptor 4

Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same.

Pharmaceutical composition

Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same.

The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Humanized monoclonal antibodies to hepatocyte growth factor

The present invention is directed toward a neutralizing monoclonal antibody to basic fibroblast growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Monoclonal antibodies to basic fibroblast growth factor

Growing community of inventors

Palo Alto, CA, United States of America

Lihong Wang